Received: Nov 26, 2025 / Accepted: Jul 28, 2026 / Published: Sep 30, 2026
African swine fever (ASF) continues to cause billions of dollars in global losses each year, disrupting pork supply chains and food security across Asia. This review analyzes the persistent gap between laboratory success and field performance of African swine fever vaccines, emphasizing live attenuated vaccines (LAVs) and hybrid next-generation platforms. It synthesizes recent findings on gene-deleted LAVs, encapsulin-based subunits, and mRNA or nanoparticle boosters that collectively aim to balance efficacy, safety, and DIVA compatibility. Key challenges include inconsistent protective efficacy, undefined immune correlates, and biosafety risks such as virulence reversion or recombination. Manufacturing constraints—dependence on porcine cell substrates, quality assurance, and scalability—compound system-level obstacles related to fragmented regulation and limited pharmacovigilance. Vietnam’s supervised rollout of NAVET-ASFVAC and AVAC ASF LIVE, with millions of doses deployed under strict monitoring, exemplifies a risk-managed model for national implementation. Looking ahead, coordinated regional governance, standardized challenge models, and harmonized regulatory frameworks are essential to translate next-generation hybrid vaccines into safe, scalable, and equitable ASF control strategies.